Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

Fig. 1

Number of patients in rPFS, PFS, and OS at 18 months. ARTA, androgen receptor-targeted agent; OS, overall survival; PFS, progression-free survival; rPFS, radiographic progression-free survival. The number correspond to a cohort of 100 patients for each treatment

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us